Pursuant to Regulation 33 of the SEBI (LODR) REgulation, 2015, the board of Directors in their Meeting held on 14.11.2025 have approved the unaudited financial results of the company for ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts more than Nifty Microcap 250 and 3.4 pts more than its Commodity Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved unaudited results for Q2 FY26 showing revenue from operations of INR 1,037 lacs (vs nil in Q2 FY25) and total income of INR 1,049 lacs. For H1 FY26, revenue from operations was INR 1,669 lacs versus nil in H1 FY25, marking the start of commercial operations. Despite the new revenue stream, the company reported a net loss of INR 24 lacs in Q2 and INR 58 lacs for H1 FY26, though losses are narrowing versus INR 51 lacs and INR 91 lacs in the corresponding prior-year periods. The auditor (A Sachdev & Co.) issued an unmodified limited review report. Other equity stands at a negative INR 5,903 lacs (accumulated losses) with cash and equivalents of just INR 5 lacs, while borrowings are INR 774 lacs.
Initial revenue traction is a positive development after a dormant FY25, but persistent losses, deeply negative reserves, and razor-thin cash reserves keep the stock fundamentally weak. Near-term price action is likely to hinge on whether revenue scale-up continues and losses keep narrowing; investors should watch for further improvement in margins and liquidity.